We first demonstrated the delivery of the c-Myc inhibitory H1 peptide described here by ELP in breast cancer cells in vitro[15], [30], and we recently demonstrated that ELP could be used to thermally target the H1 peptide to breast tumors in vivo and significantly inhibit their proliferation [13]. Here, MYC is linked to breast cancer.